A phase III study of STI-002 a biosimilar/biobetter antibody for Infliximab alone and in combination with Methotrexate for the treatment of rheumatoid arthritis
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2016
At a glance
- Drugs Infliximab biobetter (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 17 Jan 2016 New trial record
- 11 Jan 2016 According to a Sorrento Therapeutics media release, the primary end points (pain symptoms, functions, quality of life and inflammation markers) were met.
- 11 Jan 2016 According to a Sorrento Therapeutics media release, the company announced positive data from this study.